Description: ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.
Home Page: arcticzymes.com
Sykehusveien 23
Tromsø,
9294
Norway
Phone:
47 77 64 89 00
Officers
| Name | Title |
|---|---|
| Dr. Jethro Holter | Chief Exec. Officer |
| Mr. Borge Sorvoll | Chief Financial Officer |
| Dr. Marit Sjo Lorentzen | VP of Operations |
| Dr. Darren Ellis | Chief Scientific Officer |
| Mr. Alexander Johann Bjorna | Director of IP & Bus. Devel. |
| Mr. Dirk Hahneiser | VP of Bus. Devel. & Marketing |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 44.0529 |
|---|---|
| Trailing PE: | 46.8667 |
| Price-to-Book MRQ: | 12.5691 |
| Price-to-Sales TTM: | 2.4773 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 388 |